Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer

NCT05032040 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT05032040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05032040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Xencor, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 21, 2022
Completion date
December 30, 2025
Enrollment
170 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, clear cell carcinoma, endometrial cancer, metastatic castration-resistant prostate cancer (mcrpc), ovarian cancer